What Is Dapiglutide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Dapiglutide is not FDA-approved. Products sold online as dapiglutide, ZP7570, GLP-1/GLP-2 peptides, injectable dapiglutide, or “research use only” dapiglutide may carry serious safety, quality, legal, and regulatory risks.

Quick answer

Dapiglutide is an investigational long-acting dual glucagon-like peptide-1 and glucagon-like peptide-2 receptor agonist. It is also known as ZP7570 and was developed by Zealand Pharma. Dapiglutide is designed to combine GLP-1 receptor effects, such as appetite reduction and body-weight loss, with GLP-2 receptor effects, such as intestinal growth, gut-barrier support, slower intestinal transit, and possible anti-inflammatory effects. Early clinical data showed body-weight reductions in people with obesity, including up to 11.6% mean weight loss from baseline at week 28 in a Zealand phase 1b trial. However, Dapiglutide is not FDA-approved, Zealand Pharma says the program is currently paused, and strong late-stage human evidence for obesity, gut-barrier improvement, inflammation, or long-term outcomes is not established.

Key facts about Dapiglutide

What is Dapiglutide?

Dapiglutide is a long-acting dual GLP-1 and GLP-2 receptor agonist. It was developed by Zealand Pharma and is also known as ZP7570.

Zealand describes dapiglutide as a potential first-in-class peptide designed to combine the weight-loss effects of GLP-1 receptor agonism with GLP-2 receptor activity intended to improve intestinal barrier function and address obesity-related low-grade inflammation.

A PubMed-indexed preclinical study describes dapiglutide as a novel long-acting dual GLP-1R and GLP-2R agonist. A second PubMed-indexed study studied dapiglutide in preclinical short-bowel models.

The key distinction:

Dapiglutide is not just another GLP-1 drug. It is a dual GLP-1/GLP-2 receptor agonist, which makes it mechanistically different from semaglutide, liraglutide, tirzepatide, mazdutide, pemvidutide, and retatrutide.

How does Dapiglutide work?

Dapiglutide activates two receptor systems:

1. GLP-1 receptor
2. GLP-2 receptor

The GLP-1 receptor side is associated with:

• Reduced appetite
• Increased satiety
• Slower gastric emptying
• Improved glucose-related metabolic signaling
• Body-weight reduction

The GLP-2 receptor side is associated with:

• Intestinal growth
• Improved intestinal absorptive capacity
• Slower intestinal transit
• Gut-barrier support
• Possible reduction in intestinal permeability
• Possible anti-inflammatory effects through barrier biology

In plain English:

Dapiglutide is designed to reduce food intake and body weight through GLP-1 signaling while also using GLP-2 signaling to support the gut barrier and intestinal function.

That is why Zealand positioned dapiglutide as potentially differentiated for obesity-related low-grade inflammation and “leaky gut” biology.

The practical interpretation:

Dapiglutide sits in the GLP-1/GLP-2 dual-agonist category. It is conceptually different from the GLP-1/glucagon and GIP/GLP-1 drugs that dominate the obesity market.

What is Dapiglutide used for?

Dapiglutide is investigational. It is not approved for any use.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Obesity / body-weight reduction | Early clinical evidence | Phase 1b and proof-of-concept studies show weight-loss signals. Zealand reported up to 11.6% mean weight loss from baseline at week 28 in a phase 1b cohort. | Phase 3 efficacy, FDA approval, long-term durability, and broad real-world safety are not established. | | Gut-barrier support | Mechanistic / early clinical rationale | GLP-2 receptor agonism may support intestinal barrier function. | Human proof that dapiglutide improves obesity-related gut permeability or clinical outcomes is not established. | | Low-grade inflammation in obesity | Mechanistic / investigational | Zealand positioned GLP-2 activity as relevant to gut-barrier and inflammation biology. | Long, complex trials would be needed to prove anti-inflammatory clinical benefit. | | Short-bowel / intestinal insufficiency models | Preclinical | Dapiglutide showed intestinal effects in murine short-bowel and intestinal insufficiency models. | It is not approved for short bowel syndrome or intestinal failure. | | Type 2 diabetes | Early / mechanistic | GLP-1 receptor agonism may improve glucose-related biology. | Dapiglutide is not approved for diabetes, and diabetes-specific outcome evidence is limited. | | Cardiometabolic risk | Speculative / indirect | Weight loss and inflammation biology may be relevant. | Cardiovascular outcomes evidence is not established. | | Anti-aging / longevity | Unsupported | Metabolic improvement can affect health risk. | Dapiglutide is not an anti-aging or longevity therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite and weight effects may attract misuse. | It is not a bodybuilding drug. | | Online research-use dapiglutide | High risk | Sellers may market GLP-1/GLP-2 peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |

What does the research show?

Human obesity evidence

Dapiglutide has early human obesity evidence, but the program has not reached approval-level maturity.

Zealand states that dapiglutide was evaluated in a phase 1b clinical trial. In part 1, 54 participants with a median BMI of 30 received 13 weekly doses of dapiglutide or placebo across dose cohorts. Zealand reported up to 8.3% placebo-corrected mean body-weight reduction at week 13. In part 2, 30 participants received 28 weekly doses, and the estimated mean body weight decreased by 11.6% from baseline in the dapiglutide group, compared with 0.2% with placebo. No lifestyle interventions such as diet or exercise were included.

The PubMed-indexed proof-of-concept obesity trial describes dapiglutide as a dual GLP-1 and GLP-2 receptor agonist under clinical development for body-weight reduction in obesity.

The practical interpretation:

Dapiglutide has real early weight-loss signals, but the evidence is still early. It is not FDA-approved, and development is currently paused.

Development status

Zealand Pharma currently lists dapiglutide as program paused.

Zealand says development of dapiglutide was paused as part of active portfolio management, focusing investments on programs with the greatest potential for clinical differentiation and long-term value creation. Zealand also states clearly that dapiglutide is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.

A Reuters report also reported that Zealand paused dapiglutide development, citing the crowded GLP-1 market and the challenge of demonstrating differentiated anti-inflammatory effects.

The practical interpretation:

Dapiglutide is scientifically interesting, but it is not currently an active late-stage obesity approval story. The program pause matters and should be disclosed clearly.

Preclinical GLP-1/GLP-2 evidence

Dapiglutide’s biological rationale comes from dual GLP-1 and GLP-2 receptor activity.

A PubMed-indexed Journal of Parenteral and Enteral Nutrition study characterized dapiglutide and reported that it improved oral glucose tolerance, reduced intestinal transit time, and promoted intestinal growth.

A PubMed-indexed study reported that dapiglutide attenuated intestinal insufficiency in a murine model of short bowel.

The practical interpretation:

Dapiglutide has plausible preclinical intestinal and metabolic activity, but animal intestinal data do not prove human obesity, inflammation, or gut-barrier clinical benefit.

GLP-2 biology and gut-barrier rationale

The GLP-2 side of dapiglutide is the differentiating feature.

GLP-2 receptor agonists can affect intestinal growth, nutrient absorption, epithelial integrity, and intestinal transit. This is why GLP-2 drugs are relevant to short bowel syndrome and intestinal failure.

However, dapiglutide is not the same as approved GLP-2 drugs. It is a dual GLP-1/GLP-2 investigational peptide designed for metabolic disease, especially obesity.

The practical interpretation:

Dapiglutide’s GLP-2 activity is the interesting part, but also the part that needs strong human evidence. “Gut barrier support” should not be marketed as proven unless supported by controlled clinical outcomes.

FDA and substance-registration context

Dapiglutide is not FDA-approved.

The FDA/NCATS Global Substance Registration System recognizes dapiglutide as a named substance. A substance record is not drug approval.

The practical interpretation:

Being listed as a named substance does not mean dapiglutide is approved, safe, or legally marketed for consumer use.

Evidence summary

Is Dapiglutide FDA-approved?

No. Dapiglutide is not FDA-approved.

There is no FDA-approved dapiglutide product for obesity, weight loss, type 2 diabetes, gut-barrier dysfunction, leaky gut, low-grade inflammation, short bowel syndrome, metabolic disease, anti-aging, or any other use.

Zealand states that dapiglutide is investigational and has not been approved for marketing by any regulatory authority.

The key distinction:

Dapiglutide is a clinical-stage research peptide, not an approved obesity medication or gut-barrier therapy.

Is Dapiglutide legal?

Dapiglutide’s legal status depends on country, product type, prescription status, intended use, and whether it is part of a clinical trial.

For U.S. readers:

Dapiglutide is not FDA-approved, and online availability does not mean it is legally marketed for human therapeutic use.

The FDA has warned broadly about illegal or unverified GLP-1 drug ingredients entering the U.S. market. That concern applies especially to gray-market versions of investigational incretin drugs.

The blunt version:

Buying “research use only” dapiglutide online is not the same as receiving an approved metabolic medication from a legitimate pharmacy.

Is Dapiglutide banned in sports?

I did not find dapiglutide specifically named on the WADA prohibited list in the sources reviewed here.

However, dapiglutide is an investigational peptide with GLP-1 activity and GLP-2 activity. The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.

The WADA GLP-1 receptor agonist monitoring research page discusses monitoring of GLP-1 receptor agonists.

The practical advice:

Athletes should verify dapiglutide through Global DRO, WADA, or USADA before use and should avoid unapproved online peptide products.

Safety and side effects

Dapiglutide has real pharmacologic activity. It should not be treated like a harmless supplement.

Common or likely side effects, based on dapiglutide trials and incretin-drug class patterns, may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Abdominal discomfort
• Dyspepsia
• Dizziness
• Injection-site reactions
• Possible dehydration risk from severe vomiting or diarrhea
• Possible hypoglycemia risk when combined with insulin or insulin secretagogues
• Possible gallbladder-related concerns by GLP-1 class analogy
• Possible pancreatitis-related concerns by GLP-1 class analogy
• Unknown long-term cardiovascular outcomes
• Unknown long-term intestinal effects
• Unknown rare adverse-event profile outside trials
• Product-quality and sterility risks from online sources

Zealand reported that common treatment-emergent adverse events in its phase 1b trial were gastrointestinal, including nausea and vomiting, and that GI events were consistent with other incretin-based therapies.

The GLP-2 receptor activity matters.

GLP-2 activity may support intestinal growth and barrier function, but it also means dapiglutide should not be lazily described as “basically Ozempic.” It affects a different receptor system with different biological implications.

A serious evaluation of dapiglutide should separate:

Dapiglutide vs similar drugs and peptides

The key distinction:

Dapiglutide belongs in the GLP-1/GLP-2 dual-agonist category. It is not a GLP-1-only drug, not a GLP-1/glucagon drug, not a GIP/GLP-1 drug, not an amylin analog, and not an approved gut peptide.

Why is Dapiglutide sold as “research use only”?

Some online sellers may use “research use only” language to sell dapiglutide or dapiglutide-like peptides outside normal prescription channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate Dapiglutide claims online

Bottom line

Dapiglutide is an investigational long-acting dual GLP-1 and GLP-2 receptor agonist developed by Zealand Pharma. Its biological rationale is interesting: GLP-1 activity for appetite and weight loss, plus GLP-2 activity for intestinal barrier and gut-related anti-inflammatory biology. Early data show weight-loss signals, and preclinical studies support intestinal effects.

The most defensible conclusion is:

Dapiglutide is a promising but paused investigational metabolic peptide, not an approved obesity or gut-barrier therapy. It is not FDA-approved, phase 3 evidence is not established, Zealand has paused development, and readers should distinguish monitored clinical-trial dapiglutide from unapproved online products with uncertain identity, purity, sterility, concentration, and legal status.

FAQ

What is Dapiglutide?

Dapiglutide is an investigational long-acting dual GLP-1 and GLP-2 receptor agonist developed by Zealand Pharma. It is also known as ZP7570.

What does Dapiglutide do?

Dapiglutide activates GLP-1 and GLP-2 receptors. It is designed to reduce appetite and body weight through GLP-1 signaling while supporting intestinal barrier and gut-related biology through GLP-2 signaling.

Is Dapiglutide FDA-approved?

No. Dapiglutide is not FDA-approved for obesity, weight loss, gut-barrier dysfunction, inflammation, short bowel syndrome, or any other use.

Is Dapiglutide still in development?

Zealand Pharma currently lists Dapiglutide as a paused program. Zealand says development was paused as part of active portfolio management.

Is Dapiglutide the same as Ozempic?

No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Dapiglutide is a dual GLP-1 and GLP-2 receptor agonist.

Is Dapiglutide the same as teduglutide?

No. Teduglutide is a GLP-2 receptor agonist approved for short bowel syndrome patients who need parenteral support. Dapiglutide is an investigational GLP-1/GLP-2 dual agonist.

Does Dapiglutide cause weight loss?

Early clinical studies show body-weight reduction signals. Zealand reported up to 11.6% mean weight loss from baseline at week 28 in a phase 1b cohort. However, Dapiglutide is not FDA-approved as a weight-loss medication.

Does Dapiglutide help gut barrier function?

GLP-2 receptor agonism is biologically relevant to intestinal growth and barrier function, but human clinical proof that dapiglutide improves gut-barrier outcomes is not established.

Does Dapiglutide treat leaky gut?

No approved or strong clinical evidence establishes Dapiglutide as a treatment for “leaky gut.” That claim is speculative and should not be treated as proven.

Does Dapiglutide treat short bowel syndrome?

No. Dapiglutide has preclinical short-bowel model data, but it is not approved for short bowel syndrome.

Is Dapiglutide safe?

Dapiglutide has early clinical safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. Long-term safety is not established.

Is Dapiglutide legal in the U.S.?

Dapiglutide is not FDA-approved in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.

Is Dapiglutide banned in sports?

I did not find Dapiglutide specifically named on the WADA prohibited list in the sources reviewed here. GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Athletes should verify current status through WADA, USADA, or Global DRO before use.

Why do sellers call Dapiglutide “research use only”?

Sellers often use “research use only” language because Dapiglutide is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with Dapiglutide?

The biggest risks are using an investigational metabolic peptide without medical supervision, confusing early trial data with approval, ignoring that Zealand has paused development, and buying online products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. Zealand Pharma: Dapiglutide Program Paused
2. PubMed: Dapiglutide for obesity, randomized proof-of-concept trial
3. EClinicalMedicine: Dapiglutide for obesity
4. PubMed: Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
5. PubMed: The dual GLP-1 and GLP-2 receptor agonist dapiglutide improves intestinal insufficiency models
6. Wiley: Dapiglutide attenuates intestinal insufficiency in a murine model of short bowel
7. ClinicalTrials.gov: Dapiglutide for the treatment of obesity, DREAM trial
8. ClinicalTrials.gov PDF: DREAM trial protocol
9. FDA/NCATS G-SRS: Dapiglutide
10. Reuters: Zealand Pharma pauses Dapiglutide development
11. Zealand Pharma Q3 2025 Interim Report
12. USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
13. WADA: GLP-1 Receptor Agonists Monitoring Research
14. WADA: Prohibited List